Understanding how B-cell lymphomas evade the immune system
Project 1 Melnick
This study is looking into how certain genetic changes in B-cell lymphomas help these cancers avoid being attacked by the immune system, with the hope of finding new ways to improve treatment for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10847988 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which B-cell lymphomas, which often arise from the germinal center reaction, evade the immune system's regulatory checks. The team focuses on the role of specific genetic mutations in epigenetic regulatory genes, particularly CREBBP and KMT2D, and how these mutations affect immune signaling and tumor development. By examining the biochemical interactions and effects of these mutations, the research aims to uncover new insights into the immune microenvironment associated with these cancers. Patients may benefit from a deeper understanding of their condition and potential new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with B-cell lymphomas, particularly those with mutations in the CREBBP and KMT2D genes.
Not a fit: Patients with other types of cancers or those without B-cell lymphomas may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that enhance the immune response against B-cell lymphomas.
How similar studies have performed: Previous research has shown promising results in understanding the genetic and epigenetic factors involved in B-cell lymphomas, suggesting that this approach could yield significant insights.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Melnick, Ari M. — Weill Medical Coll of Cornell Univ
- Study coordinator: Melnick, Ari M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.